University of Cambridge

Cumulus Neuroscience's CNS-101 study demonstrated that at-home digital cognitive endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark ADAS-Cog 13 scale over the study time-course.

Princess Anne officially opened Insmed's new 17,000 square foot research facility in Cambridge, UK, dedicated to synthetic rescue technology for rare diseases.

The Cell and Gene Therapy Catapult made its first investment through the Cross-Catapult Investment Pilot in Spliceor, a Cambridge University spinout developing trans-splicing gene therapy for liver cancer.

The National Institute for Health and Care Research is piloting a 'Just in Time' scheme that could reduce clinical trial setup time from months to days, potentially improving patient access to trials closer to home.

A new "pill-on-a-string" capsule sponge test successfully identified 54% of Barrett's esophagus patients as low-risk, potentially eliminating the need for invasive endoscopy surveillance in these cases.

Mary Catchpole, 19, becomes the first European patient to receive leniolisib (Joenja), a newly approved targeted treatment for activated PI3-kinase delta syndrome (APDS), a rare inherited immune disorder.

Spanish National Cancer Research Centre (CNIO) scientists have developed a genomic test that predicts which patients will not respond to three common chemotherapy types, potentially sparing 20-50% of cancer patients from ineffective treatment and severe side effects.

University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.

Researchers at the University of Melbourne have developed a proteomic blood test that can analyze thousands of proteins to diagnose rare genetic diseases in children within three days, requiring only 1ml of blood from infants.

Cambridge researchers have developed a promising combination therapy using venetoclax and inobrodib that effectively targets B-cell acute lymphoblastic leukemia (B-ALL), potentially reducing the need for toxic chemotherapy.